TD Asset Management’s ADC Therapeutics ADCT Stock Holding History

TD Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-74,690	Closed	-$161K	–	1411
2023 Q2	$161K	Hold	74,690	–	–	﹤0.01%	1378
2023 Q1	$146K	Hold	74,690	–	–	﹤0.01%	1393
2022 Q4	$287K	Hold	74,690	–	–	﹤0.01%	1363
2022 Q3	$365K	Sell	74,690 -17,600	-19%	-$127K	﹤0.01%	1344
2022 Q2	$734K	Hold	92,290	–	–	﹤0.01%	1235
2022 Q1	$1.36M	Hold	92,290	–	–	﹤0.01%	1181
2021 Q4	$1.86M	Hold	92,290	–	–	﹤0.01%	1147
2021 Q3	$2.51M	Buy	92,290 +8,000	+9%	+$205K	﹤0.01%	1018
2021 Q2	$1.77M	Hold	84,290	–	–	﹤0.01%	1131
2021 Q1	$2.06M	Buy	84,290 +31,801	+61%	+$921K	﹤0.01%	1095
2020 Q4	$1.68M	Buy	+52,489	New	+$1.72M	﹤0.01%	1072

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

AlphaCentric Advisors San Juan, Puerto Rico $100M AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TD Asset Management's ADCT Position: Q3 2023 in Review

TD Asset Management sold out of ADC Therapeutics (ADCT) in Q3 2023, closing a stake of 74,690 shares — an estimated $161K sold.

TD Asset Management first reported a position in ADCT in Q4 2020 and held it in 11 quarters. The position peaked at $2.51M in Q3 2021. 41 funds tracked by Wall St. Rank hold ADCT as of Q3 2023.

TD Asset Management reported no remaining ADC Therapeutics position as of Q3 2023 after selling out during the quarter.
TD Asset Management sold 74,690 ADC Therapeutics shares in Q3 2023, an estimated $161K.
TD Asset Management first reported a position in ADC Therapeutics in Q4 2020 and held it in 11 quarters.
TD Asset Management's ADC Therapeutics position peaked at $2.51M in Q3 2021.
41 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2023.

Based on TD Asset Management's 13F filing for Q3 2023, filed 27 Oct 2023.